1. 1147PPreliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers. (23rd October 2018) Authors: Wermke, M; Alt, J; Kauh, J; Back, J; Salhi, Y; Reddy, V; Barve, M; Ochsenreither, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 96PPreliminary pharmacokinetic results from a phase I study of GBR 1302 in patients with HER2 positive cancers. (17th December 2018) Authors: Gudi, G; Ca, V; Gn, S; von Gunten, C; Fluhler, E; Back, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Beyond 'find and fix': improving quality and safety through resilient healthcare systems. (28th February 2020) Authors: Anderson, J E; Ross, A J; Back, J; Duncan, M; Snell, P; Hopper, A; Jaye, P Journal: International journal for quality in health care Issue: Volume 32:Number 3(2020) Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗